Brian McCormick’s national practice includes pharmaceutical injury, product liability, whistleblower/qui tam and False Claims Act matters involving the fraud or waste of government funds and resources.
McCormick represented individual whistleblowers in the four largest settlements in U.S. history, all against pharmaceutical companies, and assisted the U.S. government in successfully prosecuting many landmark qui tam actions, recovering more than $6 billion for U.S. taxpayers. He has represented clients in cases involving faulty medical devices and the drugs Risperdal, Seroquel, Zyprexa, Avandia, Gadolinium and Levaquin. Recently he has been appointed to the national Plaintiffs’ Steering Committee in the Risperdal and Invega product liability cases in California.
Before becoming a plaintiff’s attorney, McCormick represented Fortune 500 companies in shareholder and partnership disputes, securities litigation, corporate investigations, healthcare matters and Medicare fraud. Prior to law school, McCormick was an analyst with the FBI in Philadelphia where he researched, collected, and distilled information to distribute it to agents in FBI offices across the country.